The aim of the study was to study the clinical and laboratory efficacy and safety of tofacitinib in patients with axial spondyloarthritis (axSpA).

Material and methods. The study included 40 axSpA patients aged 18 to 55 years who were treated in the rheumatology department of the multidisciplinary clinic of the Tashkent state medical university. Based on the purpose of the study, the patients were divided into two groups: group 1- 20 patients received tofacitinib 5 mg 1 tab x 2 times, group 2 – 20 patient received sulfasalazine 500 mg 1 tab x 3 times after meals for 12 weeks.

Conclusion. After 12 weeks treatment taking tofacitinib 10 mg/day in 2/3 patients and sulfasalazine 1,5 g/day in ¼ patients with axSpA , the activity of sacroiliitis decreased. The frequency of side effects between tofacitinib and sulfasalazine did not differ significantly.

Axial spondyloarthritis, janus kinases, cytokine, sulfasalazine

Clark JD, Flanagan ME, Telliez J-B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014;57(12):5023-5038. doi:10.1021/jm401490p

Bertsias G. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. Mediterr J Rheumatol 2020;31(Suppl 1):105-111. doi:10.31138/mjr.31.1.105

Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 2021;80(7):865-875. doi:10.1136/annrheumdis-2020-219012

Chatzidionysiou K. Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium. Mediterr J Rheumatol 2020;31(Suppl 1):120-128. doi:10.31138/mjr.31.1.120

Braun J, Kiltz U, Baraliakos X. Management of Axial Spondyloarthritis – Insights into Upadacitinib. Drug Des Devel Ther 2022 Oct 19:16:3609-20.

Fragoulis GE, Pappa M, Evangelatos G, Iliopoulos A, Sfikakis PP, Tektonidou MG. Axial psoriatic arthritis and ankylosing spondylitis: same or different? A real-world study with emphasis on comorbidities. Clin Exp Rheumatol 2022 Jul;40(7):1267–72.

Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, et al. Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 2020;12.

Gialouri CG, Evangelatos G, Zhao SS, Kouna K, Karamanakos A, Iliopoulos A, et al. Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients’ perception? Mood disorders in psoriatic arthritis. Clin Exp Rheumatol 2023 Jan;41(1):159-65.

Mauro D, Nakamura A, Haroon N, Ciccia F. The gut-enthesis axis and the pathogenesis of Spondyloarthritis. Semin Immunol 2022 Jul:101607. doi:10.1016/j.smim.2022.101607

Mauro D, Simone D, Bucci L, Ciccia F. Novel immune cell phenotypes in spondyloarthritis pathogenesis. Semin Immunopathol 2021;43(2):265-77. doi:10.1007/s00281-021-00837-0

Sieper J, Poddubnyy D, Miossec P. The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019;15(12):747-57. doi:10.1038/s41584-019-0294-7

Schett G, Lories RJ, D’Agostino M-A, Elewaut D, Kirkham B, Soriano ER, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 2017;13(12):731-41. doi:10.1038/nrrheum.2017.188

Regan-Komito D, Swann JW, Demetriou P, Cohen ES, Horwood NJ, Sansom SN, et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat Commun 2020;11(1):155. doi:10.1038/s41467-019-13853-4

Papagoras C, Tsiami S, Chrysanthopoulou A, Mitroulis I, Baraliakos X. Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment. Arthritis Res Ther 2022;24(1):195.